Prognosis following an extended duration of adjuvant gemcitabine plus S ‐1 chemotherapy in patients with pancreatic ductal adenocarcinoma: analysis using inverse probability of treatment weighting

ConclusionExtended duration ( ≥30 weeks) of adjuvant GS chemotherapy in patients with PDAC was associated with an improved prognosis. These findings warrant a further prospective trial on PDAC to investigate the survival benefit of extended adjuvant chemotherapy.

Source: Journal of Hepato-Biliary-Pancreatic Sciences - April 18, 2022 Category: Gastroenterology Authors: Naru Kondo, Kenichiro Uemura, Tatsuaki Sumiyoshi, Kenjiro Okada, Shingo Seo, Hiroyuki Otsuka, Reo Kawano, Yoshiaki Murakami, Shinya Takahashi Tags: ORIGINAL ARTICLE Source Type: research